Health related quality-of-life in systemic sarcoidosis in Tunisia


Asma Kefi
Wiem Helali
Khaoula Ben Abdelghani
Mounira El Euch
Cyrine Sassi
Sami Turki
Ezzeddine Abderrahim


Introduction: Sarcoidosis is a systemic granulomatosis that can be associated with large-scale physical and mental disability, affecting the health related quality-of-life (HRQoL) of patients.

Aim: To evaluate the HRQoL of tunisian patients with sarcoidosis and to identify the factors that influence it.

Methods:We conducted an analytical, cross-sectional study collecting 31 patients with sarcoidosis according to the ATS/ERS/WASOG criteria. The evaluation of the HRQoL was assessed by two questionnaires in tunisian dialect. The generic score was the Medical Outcome Study 36-Short Form Health Survey (SF-36).The specific score used was the Sarcoidosis Health Questionnaire (SHQ).

Results : The HRQoL of our 31 patients was more affected in the three domains of the SHQ compared to the SF-36, which is in favor of the better sensitivity of the SHQ to detect the influence of the extent of sarcoidosis on the HRQoL. Factors associated with more impaired HRQoLwere: age at disease onset, age at interview, comorbidities, altered spirometry results, ocular involvement, chronic cholestasis, splenic nodules, arthralgia, organ count ≥3, lymphopenia and cholestasis at the time of the interview. Taking an immunosuppressant agent, particularly Methotrexate, was associated with HRQoL improvement. The number of relapses was the most correlated factor with an altered HRQoL, and this in several domains.

Conclusion:For an effective management of patients with sarcoidosis, a bio-psycho-social approach is now necessary in order to assess the real and global impact of the disease and to improve the HRQoL of patients. Disease-specific scores seem more reliable in achieving these goals.


Sarcoidosis, Quality of life, Questionnaire



  1. Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res 1993;2:153‑9.
  2. Demiral Y, Ergor G, Unal B, et al. Normative data and discriminative properties of short form 36 (SF-36) in Turkish urban population. BMC Public Health 2006;6:247.
  3. Guermazi M, Allouch C, Yahia M, et al. Translation in Arabic, adaptation and validation of the SF-36 Health Survey for use in Tunisia. Annals of Physical and Rehabilitation Medicine 2012;55:388‑403.
  4. Tanizawa K, Handa T, Nagai S, et al. Validation of the japanese version of the sarcoidosis health questionnaire: A cross-sectional study. Health and Quality of Life Outcomes 2011;9:34.
  5. Aggarwal AN, Sahu KK, Gupta D. Fatigue and health-related quality of life in patients with pulmonary sarcoidosis treated by oral Corticosteroids. SarcoidosisVasc Diffuse Lung Dis 2016;33:124‑9.
  6. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest 2004;125:997‑1004.
  7. De Vries J, Drent M. Quality of Life and Health Status in Sarcoidosis: A Review of the Literature. Clinics in Chest Medicine 2008;29:525‑32.
  8. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993;46:1417‑32.
  9. Tanizawa K, Handa T, Nagai S, et al. Can the Sarcoidosis Health Questionnaire predict the long-term outcomes in Japanese sarcoidosis patients? Respiratory Medicine 2019;149:1‑8.
  10. Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest 2015;147:438‑49.
  11. Mihailović-Vučinić V, Gvozdenović B, Stjepanović M, et al. Administering the Sarcoidosis Health Questionnaire to sarcoidosis patients in Serbia. J Bras Pneumol 2016;42:99‑105.
  12. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal [Internet]. 2021 dec 1 [cited2022 sept 8];58(6). Available from:
  13. Judson MA. The treatment of pulmonary sarcoidosis. Respir Med 2012;106:1351‑61.
  14. Baughman RP, Judson MA, Wells A. The indications for the treatment of sarcoidosis: Wells Law. Sarcoidosis Vasc Diffuse Lung Dis 2017;34:280‑2.
  15. Beegle SH, Barba K, Gobunsuy R, Judson MA. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des DevelTher 2013;7:325‑38.
  16. Khan NA, Donatelli CV, Tonelli AR, et al. Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med 2017;132:9‑14.
  17. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life. Am J RespirCrit Care Med 2003;168:323‑9.
  18. De Boer S, Wilsher ML. Validation of the Sarcoidosis Health Questionnaire in a non-US population. Respirology 2012;17:519‑24.
  19. Judson MA, Chaudhry H, Louis A, Lee K, Yucel R. The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med 2015;109:526‑31.
  20. Dudvarski-Ilić A, Mihailović-Vucinić V, Gvozdenović B, Zugić V, Milenković B, Ilić V. Health related quality of life regarding to gender in sarcoidosis. CollAntropol 2009;33:837‑40.